Vásquez-Awad D

Idioma: Español
Referencias bibliográficas: 27
Paginas: 47-55
Archivo PDF: 247.16 Kb.

RESUMEN

Después de 40 años, los anticonceptivos orales combinados han mostrado un perfil de seguridad óptimo que permite indicarlos a distintos grupos etarios. En años recientes se ha observado que, a la par del efecto anticonceptivo para el que fueron creados, los hormonales orales combinados ofrecen diversos efectos benéficos, ginecológicos o no, que se han estudiado con detenimiento. El propósito de este artículo es analizar, a la luz de la evidencia, los efectos benéficos no anticonceptivos de los hormonales orales combinados en mujeres no interesadas en planificar su familia. Los anticonceptivos orales combinados repercuten positivamente en la vida de las mujeres en edad reproductiva, no solo desde el punto de vista médico sino en el ámbito social, emocional, antropológico, económico y de autoestima. El control de la fertilidad ha sido uno de los avances más notorios en la lucha –que es de todos los ginecólogos– por lograr la igualdad de género. Además de los efectos anticonceptivos de los hormonales orales combinados, también son reconocidos los beneficios ginecológicos y no ginecológico de estos fármacos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Huxley A. Brave new world revisited. New York: Harper and Row, 1958:138-139. https://archive.org/stream/Brave_ New_World_Revisited/Brave%20New%20World%20 Revisited%20-%20Huxley%20%281958%29_djvu.txt

2. Peterson HB, et al. The health effects of oral contraceptives: Misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-355.

3. Panser LA, et al. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-9. https://doi.org/10.1016/0010- 7824(91)90130-8

4. van Hoof MH, et al. The use of oral contraceptives by adolescents for contraception, menstrual cycle problems or acne. Acta Obstet Gynecol Scand 1998;77(9):898-904. https://doi.org/10.1034/j.1600-0412.1998.770905.x

5. Sundell G, et al. Factors influencing the prevalence and severity of dysmenorrhea in young women. Br J Obstet Gynaecol 1990;97:588-594. https://doi. org/10.1111/j.1471-0528.1990.tb02545.x

6. Lanes SF, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-961. https://doi.org/10.1016/0002-9378(92)91371-G

7. Ross RK, et al. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. BMJ (Clin Res Ed) 1986;293(6543):359-362. https://www.bmj.com/content/ bmj/293/6543/359.full.pdf

8. Chiaffarino F, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynecol 1999;106:857-860. https://obgyn.onlinelibrary. wiley.com/doi/epdf/10.1111/j.1471-0528.1999.tb08409.x

9. Cancer and Steroid Hormone Study of the Center for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-655. https://www.nejm.org/doi/ full/10.1056/NEJM198703123161102

10. Hankinson SE, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-714.

11. Narod SA, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.

12. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined ral contraceptives: A practitioner´s guide to meta-analysis. Hum Reprod 1997;12:1851-1863.

13. Sherman ME, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10:963-968,1997.

14. Vessey M, et al. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385- 389. https://www.nature.com/articles/6603260

15. Parazzini F, et al. Contraceptive methods and risk of pelvic endometriosis. Contraception 1994;49:47-55

16. Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 1999;3:3. http://cochranelibrary-wiley.com/ doi/10.1002/14651858.CD001019/full

17. Martínez ME, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997;6:1-5. http://cebp. aacrjournals.org/content/6/1/1.full-text.pdf

18. Franceschi S, et al. Oral contraceptives and colorectal tumors: A review of epidemiologis studies. Contraception 1998;58:335-343. https://doi.org/10.1016/S0010- 7824(98)00128-0

19. Milman N, et al. Iron status in 268 Danish women aged 18-30 years: Influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998;77(1-2):13-19. https://link.springer.com/article/10.1007/s002770050405

20. Lucky AW, et al. Effectiveness of norgestimate and ethynil estradiol in treating moderates acne vulgaris. J Am Acad Dermatol 1997;37(5 pt 1):746-54. https://doi.org/10.1016/ S0190-9622(97)70112-9

21. Redmond GP, et al. Norgestimate and ethynil estradiol in the treatment of acne vulgaris: A randomized , placebocontrolled trial. Obstet Gynecol 1997;89:615-622. https:// doi.org/10.1016/S0029-7844(97)00059-8

22. Gambacciani M, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994;83:392-396.

23. Kleerekoper M, et al. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteopo- rosis Cooperative Research Group. Arch Intern Med 1991;151:1971-1976.

24. Michaelsson K, et al. Oral contraceptive use and risk of hip fracture: A case-control study. Lancet 1999;353(9163):1481-1484. https://doi.org/10.1016/ S0140-6736(98)09044-8

25. Brinton LA, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-214. https://doi.org/10.1093/ oxfordjournals.aje.a113089

26. Brennan P, et al. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident casecontrol study. Semin Arthritis Rheum 1997;26:817-823. https://www.semarthritisrheumatism.com/article/S0049- 0172(97)80025-X/pdf

27. Burkman R, et al. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190(4)(S1):S5-S22. https://doi.org/10.1016/j. ajog.2004.01.061.